Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia

The Lancet Respiratory Medicine

Volumn 5, Issue 12, 2017, Pages e35-e36

  Bermejo Martin, Jesus F ^a   Almansa, Raquel ^a   Martin Fernandez, Marta ^a   Menendez, Rosario ^b   Torres, Antoni ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD28 ANTIGEN; GRANZYME B; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; INTERLEUKIN 17; MESSENGER RNA; PROPERDIN;

ANTIGEN PRESENTATION; APACHE; B ELL DEVELOPMENT; BACTEREMIA; COMMON VARIABLE IMMUNODEFICIENCY; COMMUNITY ACQUIRED PNEUMONIA; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DROPLET DIGITAL POLYMERASE CHAIN REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HELPER CELL; HOSPITAL ADMISSION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PROCEDURES; INTENSIVE CARE UNIT; LETTER; LUNG INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MORTALITY; MORTALITY RISK; NANOSTRING TECHNOLOGY; NEPHELOMETRY; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIA; TECHNOLOGY; TRANSCRIPTOMICS; COMMUNITY ACQUIRED INFECTION; IMMUNITY; IMMUNOLOGY; PNEUMONIA; SEVERITY OF ILLNESS INDEX;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; IMMUNITY; LYMPHOCYTE COUNT; PNEUMONIA; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 85035052034     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30444-7     Document Type: Letter

References (8)

1. Bermejo-Martin, JF, Cilloniz, C, Mendez, R, et al. Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. EBioMedicine 24 (2017), 231–236.
2. de la Torre, MC, Palomera, E, Serra-Prat, M, et al. IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia. J Crit Care 35 (2016), 115–119.
3. Justel, M, Socias, L, Almansa, R, et al. IgM levels in plasma predict outcome in severe pandemic influenza. J Clin Virol 58 (2013), 564–567.
4. Coonrod, JD, Rylko-Bauer, B, Complement levels in pneumococcal pneumonia. Infect Immun 18 (1977), 14–22.
5. Davenport, EE, Burnham, KL, Radhakrishnan, J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 4 (2016), 259–271.
6. Scicluna, BP, van Vught, LA, Zwinderman, AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med 5 (2017), 816–826.
7. Bermejo-Martin, JF, Martin-Loeches, I, Rello, J, et al. Host adaptive immunity deficiency in severe pandemic influenza. Crit Care, 14, 2010, R167.
8. Almansa, R, Socias, L, Ramirez, P, et al. Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenza. Crit Care, 15, 2011, 448.